1-甲基-1H-苯并咪唑-5-羧酸甲酯 | 131020-36-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1-甲基-1H-苯并咪唑-5-羧酸甲酯
• 中文别名: 1-甲基-1H-苯并[D]咪唑-5-羧酸甲酯
• 英文名称: methyl 1-methyl-1H-benzo[d]imidazole-5-carboxylate
• 英文别名: 1-methyl-1H-benzoimidazole-5-carboxylic acid methyl ester；1-methyl 1H-benzimidazole 5-carboxylic acid methyl ester；1-methyl-1H-benzimidazole 5-carboxylic acid methyl ester；methyl 1-methyl-1H-benzimidazole-5-carbonate；methyl 1-methyl-benzimidazole-5-carboxylate；methyl 1-methylbenzimidazole-5-carboxylate
• CAS: 131020-36-5
• 化学式: C₁₀H₁₀N₂O₂
• mdl: MFCD04492113
• 分子量: 190.202
• InChiKey: HBYFGEOBNHODCG-UHFFFAOYSA-N

物化性质

• 熔点：
  109～111℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 1-methylbenzimidazole-5-carboxylate
Synonyms: Methyl 1-methyl-1,3-benzodiazole-5-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 1-methylbenzimidazole-5-carboxylate
CAS number: 131020-36-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H10N2O2
Molecular weight: 190.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基-1H-苯并咪唑-5-羧酸甲酯 在 lithium methanolate 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 生成 1-甲基-1H-苯并咪唑-5-羧酸
  参考文献：
  名称：

  [EN] COMPOUNDS HAVING A FUSED, BICYCLIC MOIETY FOR BINDING TO THE MINOR GROOVE OF DSDNA
  [FR] COMPOSES COMPORTANT UNE FRACTION BICYCLIQUE FUSIONNEE QUI SE LIE AU PETIT SILLON D'ADN DOUBLE BRIN

  摘要：

  公开号：

  WO2004099131A3
• 作为产物：
  描述：

  1H-苯并咪唑-5-羧酸 在 硫酸 、 potassium carbonate 作用下， 生成 1-甲基-1H-苯并咪唑-5-羧酸甲酯
  参考文献：
  名称：

  [EN] ARYL SUBSTITUTED OLEFINIC COMPOUNDS AS PDE10A INHIBITORS
  [FR] COMPOSÉS OLÉFINIQUES À SUBSTITUTION ARYLE EN TANT QU'INHIBITEURS DE LA PDE10A

  摘要：

  本发明提供了芳基取代烯烃化合物作为磷酸二酯酶1 0A（PDE 1 0A）抑制剂。具体来说，本文描述的化合物可用于通过抑制磷酸二酯酶1 0A酶来治疗或预防疾病、症状和/或紊乱。本文还提供了用于制备本文描述的化合物的工艺、用于合成的中间体以及它们的药物组合物。

  公开号：

  WO2011138657A1

文献信息

• [EN] 2-(4-ARYL-1H-IMIDAZOL-1-YL)ANILINE COMPOUNDS<br/>[FR] COMPOSÉS 2-(4-ARYL-1H-IMIDAZOL-1-YL)ANILINE
  申请人：UNIV COLORADO REGENTS

  公开号：WO2015171951A1

  公开（公告）日：2015-11-12

  The present invention provides compounds that are useful as vaccine adjuvants and/or antitumor agents and methods for producing and using the same. In one particular aspect of the invention, compounds of the invention are of the formula (I) where R1, R2, R3 and Ar1 are those defined herein.

  本发明提供了作为疫苗佐剂和/或抗肿瘤药物有用的化合物，以及制备和使用这些化合物的方法。在本发明的一个特定方面，本发明的化合物具有以下式（I）的结构，其中R1、R2、R3和Ar1如本文所定义。
• [EN] PRMT5 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE PRMT5 ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2014100695A1

  公开（公告）日：2014-06-26

  Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

  本文描述了式（A）的化合物，其药学上可接受的盐以及药物组合物。本发明的化合物对抑制PRMT5活性是有用的。还描述了利用这些化合物治疗PRMT5介导的疾病的方法。
• Visible-Light-Initiated Manganese Catalysis for C−H Alkylation of Heteroarenes: Applications and Mechanistic Studies
  作者：Philippe Nuhant、Martins S. Oderinde、Julien Genovino、Antoine Juneau、Yohann Gagné、Christophe Allais、Gary M. Chinigo、Chulho Choi、Neal W. Sach、Louise Bernier、Yvette M. Fobian、Mark W. Bundesmann、Bhagyashree Khunte、Mathieu Frenette、Olugbeminiyi O. Fadeyi

  DOI：10.1002/anie.201707958

  日期：2017.11.27

  A visible‐light‐driven Minisci protocol that employs an inexpensive earth‐abundant metal catalyst, decacarbonyldimanganese Mn2(CO)10, to generate alkyl radicals from alkyl iodides has been developed. This Minisci protocol is compatible with a wide array of sensitive functional groups, including oxetanes, sugar moieties, azetidines, tert‐butyl carbamates (Boc‐group), cyclobutanes, and spirocycles. The

  已经开发了一种可见光驱动的Minisci协议，该协议采用了廉价的地球上富足的金属催化剂十羰基二锰Mn 2（CO）10从烷基碘生成烷基。该Minisci方案与各种敏感的官能团兼容，包括氧杂环丁烷，糖部分，氮杂环丁烷，氨基甲酸叔丁酯（Boc组），环丁烷和螺环。复杂的含氮药物的后期功能化证明了该方案的鲁棒性。光物理和DFT研究表明，光传播的链反应机制由传播。Mn（CO）5。限速步骤是通过碘从烷基碘中提取碘。Mn（CO）5。
• Cu-Catalyzed C–H Allylation of Benzimidazoles with Allenes
  作者：Yaxi Dong、Bernhard Breit

  DOI：10.1021/acs.orglett.1c02346

  日期：2021.9.3

  CuH-catalyzed intramolecular cyclization and intermolecular allylation of benzimidazoles with allenes have been described. The reaction proceeded smoothly with the catalytic system of Cu(OAc)2/Xantphos and catalytic amount of (MeO)2MeSiH. This protocol features mild reaction conditions and a good tolerance of substrates bearing electron-withdrawing, electron-donating, or electron-neutral groups. A

  已经描述了 CuH 催化的苯并咪唑与丙二烯的分子内环化和分子间烯丙基化。在Cu(OAc) 2 /Xantphos的催化体系和催化量的(MeO) 2 MeSiH的作用下，反应顺利进行。该协议具有温和的反应条件和对带有吸电子、给电子或电子中性基团的底物的良好耐受性。针对该氢化铜催化体系提出了一种新的催化机理。
• New phenylhydrazone derivatives and their use as pharmaceuticals
  申请人：Arteria

  公开号：EP2338879A1

  公开（公告）日：2011-06-29

  A compound of general formula (I) : a process for preparing the same, a pharmaceutical composition comprising said compound comprising such compound and its use for treating or preventing diseases related to the metabolic syndrome such as hepatic and cardiovascular diseases.

  通用公式(I)的化合物：制备该化合物的方法，包括该化合物的药物组合物，以及用于治疗或预防与代谢综合征相关的疾病，如肝脏和心血管疾病的用途。